ASH: Rivaroxaban Prevents Blood Clots in At-Risk Cancer Patients
Risk for patients in rivaroxaban group reduced during the on-treatment period
Thromboembolism
Patient Education Ups VTE Prophylaxis in Hospital Setting
Targeted patient-centered intervention reduces nonadministration of pharmacologic prophylaxis.
Risk of Venous Thromboembolism Recurrence High
At 6 months, rates for provoked, unprovoked, cancer-related VTE are 6.8, 6.92, 9.06 per 100 person-years
Peri-Op RBC Transfusions Linked to Postoperative VTE
Perioperative red blood cell transfusion linked to increased adjusted odds of VTE, DVT, PE.
Reduced-Dose Anticoagulants Feasible for Extended VTE Tx
May be as effective as full-dose direct oral anticoagulants for extended-duration treatment.
Rivaroxaban Linked to Low VTE Recurrence in Active Cancer
Lower rate of VTE recurrence, but higher clinically relevant non-major bleeding versus dalteparin.
Pharmacomechanical Thrombolysis Does Not Cut Post-thrombotic Syndrome
Pharmacomechanical thrombolysis used with anticoagulation treatment, did not decrease post-thrombotic syndrome risks but increased major bleeding risks in patients with acute proximal DVT.
FDA Clears Betrixaban for VTE Prophylaxis
Fewer VTE events were observed in the betrixaban than enoxaparin arm.
Venous Thromboembolism Risk Elevated in Dialysis Patients
VTE is more common among dialysis patients than in the general population, and the risk is highest in the first 6 months after dialysis initiation.
VTE Linked to Higher Death, Graft Loss Risk in Transplant Recipients
Venous thromboembolism is associated with a 4.1-fold increased risk of death and a 2.3-fold increased risk of death-censored graft loss among kidney transplant recipients.
Next post in ATC 2017
